Since the initial clinical approval in the late 1990s and remarkable anticancer effects for
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …

In the past two decades, several molecular targeted inhibitors have been developed and
evaluated clinically to improve the survival of patients with cancer. Molecular targeted …

Tyrosine kinase inhibitors (TKIs) that target epidermal growth factor receptor (EGFR) have
dramatically improved progression-free survival in non-small-cell lung cancer (NSCLC) …

Epidermal growth factor receptor (EGFR) is an oncogenic drug target and plays a critical role
in several cellular functions including cancer cell growth, survival, proliferation …

Osimertinib (OB) is a third-generation irreversible tyrosine kinase inhibitor targeting the
epidermal growth factor receptor (EGFR), overexpressed in non-small cell lung cancer …

Introduction Non-small cell lung cancer (NSCLC) is often caused by molecular alterations
that can be detected by predictive biomarkers including mutations or amplifications of …

The emergence of tyrosine kinase inhibitors and immune checkpoint inhibitors has paved a
new era for the management of non‐small cell lung cancer, which has for many years lacked …

Introduction: Lung cancer is the most prevalent malignant tumors worldwide. Over the past
decade, the emergence of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR …

Purpose There is a lack of real‐world data in Asian populations for brigatinib, a next‐
generation anaplastic lymphoma kinase (ALK) inhibitor for patients with non‐small cell lung …

Background For advanced tumors that lack specific oncogenic alteration and are resistant to
chemotherapy, anti-angiogenesis therapy or immunotherapy or a combination of the two are …